PINE BROOK, N.J. — Alvogen has entered an agreement to buy a portfolio of four U.S. pharmaceutical products from Pfizer Inc. Under the deal announced Wednesday, Alvogen plans to acquire three injectable products — Clindamycin, Voriconazole and Melphalan — and one inhaled solution product, Acetylcysteine. Financial terms of the deal weren’t disclosed. Two of the
NEW YORK — Pfizer Inc. has entered into an agreement with Synthon to acquire the exclusive U.S. commercialization rights for glatiramer acetate, a potential generic version of Teva Pharmaceuticals’ Copaxone for the treatment of relapsing remitting multiple sclerosis (RRMS). Pfizer said Monday that under the agreement, it will have exclusive rights to commercialize both dosage
NEW YORK — Pfizer Inc. plans to buy GlaxoSmithKline’s quadrivalent meningitis ACWY vaccines, Nimenrix and Mencevax, for about $130 million. (NYSE: PFE) today announced that it has entered into an agreement with GlaxoSmithKline (GSK) to acquire its quadrivalent meningitis ACWY vaccines, Nimenrix and Mencevax, for a total consideration of approximately $130 million (€115 million). Pfizer
